Literatur: Heparin induzierte Thrombozytopenie

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

  • 1. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977; 3:160. [PubMed 322290]
  • 2. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e495S. [PubMed 22315270]
  • 3. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:340S. [PubMed 18574270]
  • 4. Chong BH, Castaldi PA. Platelet proaggregating effect of heparin: possible mechanism for non-immune heparin-associated thrombocytopenia. Aust N Z J Med 1986; 16:715. [PubMed 3469974]
  • 5. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008; 112:2607. [PubMed 18809774]
  • 6. Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009; 135:1651. [PubMed 19497901]
  • 7. Morris TA, Castrejon S, Devendra G, Gamst AC. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. Chest 2007; 132:1131. [PubMed 17646239]
  • 8. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007; 131:1644. [PubMed 17400685]
  • 9. Warkentin TE, Eikelboom JW. Who is (still) getting HIT? Chest 2007; 131:1620. [PubMed 17565011]
  • 10. Oliveira GB, Crespo EM, Becker RC, et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008; 168:94. [PubMed 18195201]
  • 11. Crespo EM, Oliveira GB, Honeycutt EF, et al. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J 2009; 157:651. [PubMed 19332191]
  • 12. Stein PD, Hull RD, Matta F, et al. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 2009; 122:919. [PubMed 19682670]
  • 13. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115:1797. [PubMed 19965682]
  • 14. Yusuf AM, Warkentin TE, Arsenault KA, et al. Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. A systematic review. Thromb Haemost 2012; 107:8. [PubMed 22072088]
  • 15. Heeger PS, Backstrom JT. Heparin flushes and thrombocytopenia. Ann Intern Med 1986; 105:143. [PubMed 3717797]
  • 16. Muslimani AA, Ricaurte B, Daw HA. Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Hematol 2007; 82:652. [PubMed 17177192]
  • 17. Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117:1370. [PubMed 20959601]
  • 18. Greinacher A, Holtfreter B, Krauel K, et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118:1395. [PubMed 21659541]
  • 19. Stribling WK, Slaughter TF, Houle TT, Sane DC. Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J 2007; 153:900. [PubMed 17540189]
  • 20. Kowalska MA, Krishnaswamy S, Rauova L, et al. Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. Blood 2011; 118:2882. [PubMed 21772054]
  • 21. Chudasama SL, Espinasse B, Hwang F, et al. Heparin modifies the immunogenicity of positively charged proteins. Blood 2010; 116:6046. [PubMed 20852126]
  • 22. Cines DB, Rauova L, Arepally G, et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 2007; 22:31. [PubMed 17285619]
  • 23. Suvarna S, Espinasse B, Qi R, et al. Determinants of PF4/heparin immunogenicity. Blood 2007; 110:4253. [PubMed 17848616]
  • 24. Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 2010; 8:30. [PubMed 19793190]
  • 25. Gruel Y, Pouplard C. Post-operative platelet count profile: the most reliable tool for identifying patients with true heparin-induced thrombocypenia after cardiac surgery. J Thromb Haemost 2010; 8:27. [PubMed 19817999]
  • 26. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med 1996; 128:376. [PubMed 8833886]
  • 27. Schallmoser K, Drexler C, Rohde E, et al. The particle gel immunoassay as a rapid test to rule out heparin-induced thrombocytopenia? J Thorac Cardiovasc Surg 2009; 137:781. [PubMed 19258119]
  • 28. Pauzner R, Greinacher A, Selleng K, et al. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009; 7:1070. [PubMed 19291166]
  • 29. Martin-Toutain I, Settegrana C, Ankri A. High levels of heparin-platelet factor 4 antibodies in patients with pseudothrombocytopenia: risk of misdiagnosis. J Thromb Haemost 2009; 7:1416. [PubMed 19490414]
  • 30. Warkentin TE, Greinacher A, Gruel Y, et al. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 9:2498.
  • 31. Bakchoul T, Giptner A, Najaoui A, et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7:1260. [PubMed 19422442]
  • 32. Pouplard C, Leroux D, Regina S, et al. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010; 103:145. [PubMed 20062918]
  • 33. Whitlatch NL, Kong DF, Metjian AD, et al. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 2010; 116:1761. [PubMed 20508160]
  • 34. Selleng S, Schreier N, Wollert HG, Greinacher A. The diagnostic value of the anti-PF4/heparin immunoassay high-dose heparin confirmatory test in cardiac surgery patients. Anesth Analg 2011; 112:774. [PubMed 21385980]
  • 35. Ruf KM, Bensadoun ES, Davis GA, et al. A clinical-laboratory algorithm incorporating optical density value to predict heparin-induced thrombocytopenia. Thromb Haemost 2011; 105:553. [PubMed 21264443]
  • 36. Baroletti S, Hurwitz S, Conti NA, et al. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med 2012; 125:44. [PubMed 22075045]
  • 37. Nagler M, Fabbro T, Wuillemin WA. Prospective evaluation of the interobserver reliability of the 4Ts score in patients with suspected heparin-induced thrombocytopenia. J Thromb Haemost 2012; 10:151. [PubMed 22060821]
  • 38. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010; 8:2642. [PubMed 20854372]
  • 39. Tschudi M, Lämmle B, Alberio L. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. Blood 2009; 113:2402. [PubMed 19059879]
  • 40. Wisler JW, Washam JB, Becker RC. Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia. J Thromb Thrombolysis 2012; 33:287. [PubMed 22271374]
  • 41. Warkentin TE, Davidson BL, Büller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140:366. [PubMed 21393394]
  • 42. Blackmer AB, Oertel MD, Valgus JM. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues. Ann Pharmacother 2009; 43:1636. [PubMed 19737996]
  • 43. Baroletti S, Labreche M, Niles M, et al. Prescription of fondaparinux in hospitalised patients. Thromb Haemost 2009; 101:1091. [PubMed 19492152]
  • 44. Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 2011; 9:2389. [PubMed 21883878]
  • 45. Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost 2010; 16:663. [PubMed 19825921]
  • 45. Krauel K, Hackbarth C, Fürll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012; 119:1248. [PubMed 22049520]
  • 46. Fieland D, Taylor M. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies. Ann Pharmacother 2012; 46:e3. [PubMed 22202498]
  • 47. Refaai MA, Chuang C, Menegus M, et al. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8:1419. [PubMed 20345717]
  • 48. Wanaka K, Matsuo T, Matsuo M, et al. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8:616. [PubMed 20050999]
  • 49. Warkentin TE, Pai M, Cook RJ. Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. J Thromb Haemost 2012; 10:148. [PubMed 22018307]
  • 50. Welsby IJ, Um J, Milano CA, et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010; 110:30. [PubMed 19933539]
  • 51. Despotis GJ, Avidan MS. Plasma exchange for heparin-induced thrombocytopenia: is there enough evidence? Anesth Analg 2010; 110:7. [PubMed 20023181]
  • 52. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thrombosis and Haemostasis 2006; 4: 759-765 [PubMed 16634744]

 

  top |

 

 
© 2022 Prof. Dr. J. Braun